Berberine GLP 1 trial lifts natural hormone levels but supplier rejects weight loss reading

A berberine GLP 1 trial has drawn a public warning from the company behind it. Zeus Hygia Life Sciences, the Indian developer of the berberine extract Metaberine, told NutraIngredients on 2 November that its published results should not be read as proof of weight loss. The two week crossover study in 36 adults reported higher blood levels of the body's own GLP 1 hormone and lower glucose. The weight gap against placebo was about 0.35 kg, according to the trade outlet.

What the Metaberine study measured

The paper behind the berberine GLP 1 trial appeared on 28 July 2026 in the International Journal of Clinical Trials, and two of its five authors list Zeus Hygia as their employer. The team enrolled 36 healthy adults with a mean age of 39.9 years and a mean BMI of 25.8. All had fasting glucose above the normal range but below the usual threshold for diabetes. Each person took the extract for 14 days and a placebo for 14 days, in random order, with a one week washout in between. Neither participants nor study staff knew which product was given. The paper names blood glucose during an oral glucose tolerance test as the primary outcome. Plasma GLP 1, blood lipids and safety were secondary measures.

On those measures, the authors report gains for the extract. Average fasting glucose fell several times more on the extract than on placebo, the paper reports. Total glucose exposure during the tolerance test fell 13.5% and the glucose peak fell 12.7%. Fasting endogenous GLP 1 rose 29% and the after meal level rose 22%, while placebo produced little change. Total cholesterol and LDL fell, and HDL rose. The authors state that every participant finished the study and that no adverse events were linked to the supplement. Weight was not a headline outcome in the abstract. NutraIngredients reports that weight held roughly level on the extract and rose slightly on placebo, a statistically significant difference of about 0.35 kg, or under one pound.

Supplier warns brands against weight loss claims

Speaking to NutraIngredients, Zeus Hygia's senior business development manager, Mouli Srikar Avileli, said weight loss was never what the trial set out to test. A two week study in adults with a mean BMI just above 25 cannot show whether a supplement causes weight loss, and the company now says so itself. Avileli said brands should draw a clear line between support for the body's own GLP 1 response and prescription GLP 1 drugs. "These are not equivalent approaches, and consumers should not be led to expect comparable weight-loss results from a botanical supplement," he said. The statement matters because the supplier sells the ingredient to brands, and those brands write the claims that shoppers later see on labels and in advertising.

A two week study in adults with a mean BMI just above 25 cannot show whether a supplement causes weight loss, and the company now says so itself.

Avileli said brands should focus on the glucose results and the endogenous GLP 1 response. He added that weight management claims "should be supported by appropriate clinical evidence rather than inferred solely from changes in GLP-1 levels." He also said the findings suggest the extract "may support metabolic health" through the body's natural incretin response. Those are company statements, not conclusions from an independent review. The caution has limits too. The company did not step back from the paper's glucose and lipid claims, and it still describes a separate absorption study in which, it says, its extract reached far higher blood levels than a standard berberine powder. That study was not reviewed for this report, and the full NutraIngredients interview gives no journal reference for it.

Berberine is not a GLP 1 receptor agonist

Berberine is a plant alkaloid, not a peptide, and not a drug that binds the GLP 1 receptor. It has spread online under the nickname nature's Ozempic, and NutraIngredients links that label to a rise in demand. UCLA Health says berberine is thought to act mainly through AMPK, an enzyme that controls how cells use energy, rather than by copying a gut hormone. GLP 1 receptor agonists such as semaglutide work differently. They are designed to switch on the receptor directly and steadily, and they reach patients only after regulators review large trials of weight, blood sugar and safety. A modest rise in the body's own hormone over two weeks is a different kind of signal, and it says nothing yet about appetite or lasting weight change.

UCLA Health also lists downsides for anyone who treats a berberine supplement as harmless because it is sold without a prescription. It says berberine may cause nausea, bloating, pain and diarrhea, and headaches have been reported. It may interact with anti rejection drugs taken after an organ transplant, and it could strengthen the effect of diabetes medicines. UCLA Health also warns that it can be harmful to infants through a buildup of bilirubin, which is relevant in pregnancy and breastfeeding. A UCLA Health dietitian described berberine as a dietary supplement rather than a proven medication. The same gap between marketing and human data runs through unapproved peptide products, where much of the support comes from animal or cell studies.

What comes next for the berberine evidence

Several features of the berberine GLP 1 trial limit what it can show. It was small and short, and it enrolled healthy adults, not people with obesity or diabetes. GLP 1 was a secondary outcome, so the study was not built around it. Two authors list the supplier as their employer, and the paper cites a company technical monograph among its references. Glucose and lipid results over 14 days do not show whether any benefit lasts. Our guide to weight loss trial headlines explains why duration, comparator and population matter before any percentage does. For scale, the petrelintide phase 2 study followed weight for 28 weeks against placebo, and even that drug was not tested against a GLP 1 medicine.

Avileli confirmed that a second clinical study is underway, measuring changes in BMI and waist circumference. He said its findings should show whether the metabolic effects seen so far turn into measurable weight management outcomes. The NutraIngredients report gives no start date, size, registry number or expected readout, so the design cannot yet be checked. Avileli also said longer comparative studies would be needed to show whether the lower daily amount the company promotes improves adherence or tolerability. Until those data appear, the published evidence covers short term glucose, lipid and hormone markers in 36 people. It does not cover lasting weight change, long term safety, or any direct comparison with prescription GLP 1 drugs.

Conclusion

The berberine GLP 1 trial reports a rise in natural GLP 1 and lower glucose over two weeks, plus a weight gap of about 0.35 kg that its own supplier says is not weight loss evidence. The study was small, short and partly company authored. A second trial on BMI and waist size is underway, but its design and timing are not public. Readers should treat the result as an early metabolic signal, not as a substitute for approved medicines.